Bio & health

Novo Nordisk says the FDA extended its review while manufacturing-site remediation continues; the company reports no new action date.

A targeted niclosamide formulation reduced lesion burden and pain-associated behavior in a mouse model; human efficacy remains untested.

CAR-T resets, antigen-specific tolerance, engineered regulatory T cells and AI-assisted tools share one aim: retrain the immune system rather than only silence it. Most of the evidence is still early.

The companies are expanding their immunology collaboration with a new group of antibody medicines.

Nature examines coral heat stress alongside experimental work on microbial probiotics and sound-based interventions.

ARPA-H says the program will combine adaptive trial design, computational models and real-time analysis; STAT reports that funding details were not included in the initial announcement.

A clinical study describes a tick-associated virus identified among patients with febrile illness in China.

A 15-participant phase 1a study reported sustained lipid reductions one year after a single infusion.

A newly described tick-borne virus was identified in a study of febrile patients in China.

The reported viral sequences have not yet been shown to perform a CRISPR-like function.

A small first-in-human study reported sustained lipid reductions at one-year follow-up.

A preprint describes Minerva, a genome-language-model framework for mapping sequence interactions; the reported viral repeat patterns still lack confirmed function.

A mouse study found that tirzepatide activated brown fat through effects not explained by reduced food intake alone.

The reported sequence pattern is a research lead; its biological function has not been established.

The approval adds a weekly basal insulin option for adults with type 2 diabetes; Lilly says its Phase 3 program included more than 3,400 participants.

A Rutgers analysis of FDA dockets found that most comments were form letters, with many traceable to tobacco-industry campaigns.

Biomedical coverage describes AI in lab workflows, clinical trials and radiology.

Two reports raise different questions about GLP-1 medicines and weight-related outcomes.

Public-health reporting on a U.S. outbreak sits alongside research coverage on emerging infectious diseases.

The FDA approved Onswik, Lilly’s once-weekly basal insulin for adults with type 2 diabetes.

An FDA advisory panel backed Grail’s multi-cancer blood test on benefit-risk questions; the agency has not made its approval decision.

A claims-based study reported nutritional deficiency diagnoses among pediatric GLP-1 receptor agonist users.

A UK Biobank analysis linked measured sleep stages with later disease incidence across a broad set of outcomes.

Deployment research focused on how AI changes clinical roles and how its outcomes should be measured.

The panel vote moves multi-cancer early detection toward an FDA decision that also gates insurance coverage.

New papers tested clinical LLMs on stability, bias and reproducibility rather than headline accuracy.

Registry updates showed new and established sponsors across RAS inhibition, prostate, uterine and brain cancers.

Investors are returning to bone-loss therapies as evidence for common supplements looks thin.

A preprint used genomic language modelling to design biosynthetic pathways while clinical work pushed new biomarkers.

New work argues the human and workflow context around a clinical AI matters more than how it explains itself.

Machine-learning prediction and monitoring studies clustered around acute and critical care.

Cancer news spanned an FDA advisory vote, a new approval and registered combination trials.

Novo's Medicare pricing terms and fresh evidence on stopping GLP-1 drugs both landed the same day.

AI-assisted modelling and triage tools met a resurgent filovirus and a deep-time lesson on plague.

Brain science ranged from a two-organ hypothesis to implants, long-COVID imaging and dementia prediction.

Resilience, not only pathology, is emerging as the predictive variable in dementia research.

A Galleri advisory-committee vote, a Lilly approval and a radiopharma merger set the day's regulatory tone.

Clinical AI moved from benchmarks toward deployment — and one paper flagged a gap between algorithmic scores and decisions.

Editing and RNA therapies advanced, and researchers solved a 50-year mystery by finding a new human blood group.

A capital-markets-day reset for Novo landed alongside a meta-regression on GLP-1 stroke and cognitive outcomes.

Flu antigenic drift, repeated SARS-CoV-2 introductions and a surging Ebola relative point to the value of early warning.

An effectiveness study and a trust-and-information story show the two halves of the vaccination problem.

New disease models, an Amish cohort study and an analysis of repurposing candidates all point at the same target from different directions.

A first-in-human neuromodulation trial overlaps with basic work on how amygdala neurons join valence-related ensembles and with a developmental study of anxiety.

Papers on AI in trials, patient-facing generative AI and a geriatrician's commentary converge on evaluation as the binding constraint.

Observational diet research and two cardiovascular studies on gut microbiota and on religiosity add to the evidence base without settling causation.

An approval for an ultra-rare disease arrived alongside preclinical gene-therapy work and a review of CRISPR-based biosensors.

New and updated registry entries spanned AI cardiac imaging, a supplement trial, metabolic and oncology studies, and an AI review of diabetes self-management.